The Appraisal Committee was due to meet on 19th January 2016 to discuss the use of cobimetinib in combination with vemurafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma [ID815]. As the company was unable to provide an economic analysis in their submission, we are suspending the appraisal while we consider the next steps. Consequently the discussion of this technology at the committee meeting on the date above has been cancelled. We are considering options for rescheduling this appraisal with the company.